Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic…

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte R, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:243344.

Article CAS PubMed Google Scholar

Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2022;10:ofac687.

Article PubMed PubMed Central Google Scholar

Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21:162228.

Article CAS PubMed Google Scholar

Solano C, Gimnez E, Albert E, Piana JL, Navarro D. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: a narrative review. J Med Virol. 2023;95:e29005.

Article CAS PubMed Google Scholar

Gimnez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernndez-Boluda JC, et al. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Transpl Infect Dis. 2023;25:e1402.

Article Google Scholar

Solano C, Gimnez E, Piana JL, Vinuesa V, Poujois S, Zaragoza S, et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant. 2016;51:71822.

Article CAS PubMed Google Scholar

Huntley D, Talaya A, Gimnez E, Martnez A, Hernndez-Boluda JC, Hernani R, et al. Features of cytomegalovirus DNAemia Blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2020;26:9727.

Article CAS PubMed Google Scholar

Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirusspecific Tcell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:3443.

Article CAS PubMed PubMed Central Google Scholar

Gabanti E, Borsani O, Colombo AA, Zavaglio F, Binaschi L, Caldera D, et al. Human cytomegalovirusspecific Tcell reconstitution and lateonset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transplant Cell Therapy. 2022;28:211.e1211.e9.

Article CAS Google Scholar

Lauruschkat CD, Muchsin I, Rein A, Erhard F, Grathwohl D, Dlken L, et al. CD4+T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis. Front Immunol. 2023;14:1148841.

Article CAS PubMed PubMed Central Google Scholar

Zavaglio F, Vitello D, Bergami F, Arena F, Borsani O, Colombo AA, et al. Human Cytomegalovirus (HCMV)-specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients. J Clin Virol. 2023;165:105519.

Article CAS PubMed Google Scholar

Lauruschkat CD, Muchsin I, Rein AF, Erhard F, Grathwohl D, Dlken L, et al. Impaired T and memory-like NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation. Blood Adv. 2024;8:296779.

Originally posted here:
Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic...